Xenetic Biosciences, Inc. (NASDAQ:XBIO) | WebDisclosure

Basculer en Français

8295	Companies
114810	Keywords
55260	Articles
62423	Press releases

Headlines Articles Press releases Xenetic Biosciences, Inc.

Home
Companies
Xenetic Biosciences, Inc.

BRIEF

published on 11/13/2024 at 14:35, 7 days 19 hours ago

Xenetic Biosciences publie ses résultats financiers du troisième trimestre 2024

Résultats Financiers Développement Clinique Biosciences Xénétiques Plateforme D'oncologie DNase Partenariats Institutionnels
BRIEF

published on 11/13/2024 at 14:35, 7 days 19 hours ago

Xenetic Biosciences Reports Q3 2024 Financial Results

Financial Results Xenetic Biosciences Clinical Development DNase Oncology Platform Institutional Partnerships
PRESS RELEASE

published on 11/13/2024 at 14:30, 7 days 19 hours ago

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
Xenetic Biosciences reports Q3 2024 financial results, progress in DNase-based platform for oncology, partnership with institutional collaborators, and $6.8 million cash balance

Xenetic Biosciences Oncology Q3 2024 Financial Results Institutional Partnerships DNase-based Platform
BRIEF

published on 11/12/2024 at 15:05, 8 days 18 hours ago

Xenetic Biosciences annonce des résultats précliniques positifs pour la thérapie par DNase I et anti-CTLA-4 dans le cancer colorectal

Immunothérapie Biosciences Xénétiques Données Précliniques Thérapie À L'ADNase I Carcinome Colorectal
BRIEF

published on 11/12/2024 at 15:05, 8 days 18 hours ago

Xenetic Biosciences Reports Positive Preclinical Results for DNase I and Anti-CTLA-4 Therapy in Colorectal Cancer

Xenetic Biosciences Preclinical Data Immunotherapy DNase I Therapy Colorectal Carcinoma
PRESS RELEASE

published on 11/12/2024 at 15:00, 8 days 18 hours ago

Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
Positive preclinical data on systemic DNase I combined with CTLA-4 antibody presented at SITC 2024, targeting NETs to enhance antitumor immunity and generate immunological memory in MSS/MMRp CRC tumors

DNase I SITC 2024 CTLA-4 Antibody Antitumor Immunity Immunological Memory
BRIEF

published on 11/07/2024 at 15:05, 13 days 18 hours ago

Xenetic Biosciences étend son partenariat avec Scripps pour renforcer son programme d'oncologie DNase

Traitement Du Cancer Collaboration En Recherche Oncologie DNase Thérapie Par Cellules CAR-T Développement Préclinique
BRIEF

published on 11/07/2024 at 15:05, 13 days 18 hours ago

Xenetic Biosciences Extends Partnership with Scripps to Boost DNase Oncology Program

Cancer Treatment Research Collaboration CAR T-cell Therapy DNase Oncology Preclinical Development
PRESS RELEASE

published on 11/07/2024 at 15:00, 13 days 18 hours ago

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Xenetic Biosciences extends Research Funding and Option Agreement with The Scripps Research Institute to advance DNase-based oncology program, targeting cancer with NETs via systemic DNase and CAR T-cell therapies

Xenetic Biosciences Cancer Treatment Research Funding DNase-based Oncology The Scripps Research Institute
BRIEF

published on 10/22/2024 at 14:50, 29 days 19 hours ago

Xenetic Biosciences' Abstract Accepted for Presentation at SITC 2024

Xenetic Biosciences Cancer Treatment Immuno-oncology DNase Platform SITC 2024

1 2 ... 4

Accesswire

Published on 11/21/2024 at 09:00, 58 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 23 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 33 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 9 hours 58 minutes ago

Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 10 hours 58 minutes ago

Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 09:41, 16 minutes ago

Original-Research: 2G Energy AG (von First Berlin Equity Research GmbH): Buy
Published on 11/21/2024 at 09:01, 56 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 08:59, 58 minutes ago

Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 58 minutes ago

Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 42 minutes ago

EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.

Les Echos

Published on 11/21/2024 at 06:58, 3 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 3 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 3 hours ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 50 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 38 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE